Regulatory Functions of MicroRNAs in Cancer Pathogenesis

Mahafarin Maralani1,2, Behzad Baradaran3, Khalil Hajiasgharzadeh3,4, Marc Peeters1

1 Department of Medical Oncology, MOCA, University Hospital Antwerp (UZA), Antwerp, Belgium
2 Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
3 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
4 Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

Received: 20 Mar. 2020; Accepted: 24 Aug. 2020

Abstract- MicroRNAs (miRNAs) are a large family of evolutionary conserved small non-coding RNA molecules that firstly discovered in 1993. They regulate gene expression of about 50% of protein-coding genes at the post-transcriptional level. MiRNAs can target numerous messenger RNAs and subsequent misexpression of them can affect many different signaling pathways. They are playing a pivotal role in cancer development by regulation of the genes expression which involved in the proliferation, survival, differentiation, apoptosis or metastasis of the cancer cells. Several treatment approaches such as inhibition of oncomiRs and restoration of tumor suppressor miRNAs have been established in certain types of cancers and some other miRNA-based strategies are in development for cancer prevention and treatment. Nowadays, cancer is the most important target of miRNA therapeutics and the specific mechanisms by which miRNA mediates cancer pathways needs more research and study.

© 2020 Tehran University of Medical Sciences. All rights reserved.
Acta Med Iran 2020;58(11):544-551.

Keywords: MicroRNA; Cancer; Proliferation; Metastasis; Therapeutic molecule

Introduction

MicroRNAs (miRNAs) are a large family of evolutionary conserved single-stranded small RNA molecules which occur as non-coding RNAs of 19-24 nucleotides in length (1,2). MiRNAs regulate gene expression of about 50% of any protein-coding gene at the posttranscriptional level (3). In the posttranscriptional level, miRNAs act through the degradation of their target mRNA or translational inhibition of the entitled mRNA (4). MiRNA coding genes are located either in intergenic regions or in the introns and are transcribed by RNA polymerase II into long primary transcripts called primary miRNAs (pri-miRNAs) (5). In the nucleus, these are processed by RNAase III endonuclease Drosha and double-stranded RNA-binding protein Pasha, into a structure called precursor miRNAs (pre-miRNAs) (6). In the nucleus, these are processed by RNAase III endonuclease Drosha and double-stranded RNA-binding protein Pasha, into a structure called precursor miRNA (pre-miRNA) (6). Pre-miRNAs are transported to the cytoplasm. There, they are cleaved, and a short RNA duplex molecule is generated (7). Later a helicase forms the mature miRNA. Mature miRNA is then assembled into the RNA induced silencing complex (RISC) (8,9). RISC regulates target mRNA’s function by binding to it and silencing its expression (10-12). In addition, by acting on regulatory sequences of their target gene, miRNAs can promote the expression (13). MiRNAs mostly can target numerous miRNAs, thus in case of misexpression in a single miRNA, expression of several hundreds of proteins can be disrupted, and many different signaling pathways may be affected. This also can cause cancerous transformation (14). The processing of miRNAs is demonstrated in Figure 1.

MicroRNA discovery

MicroRNA was first discovered by Victor Ambros’ laboratory in 1993 during research on Caenorhabditis elegans. Simultaneously, Gary Ravkun reported the first miRNA target gene, which resulted in the identification of a novel mechanism of posttranscriptional gene regulation (15). Later, Ravkun and Horvitz found let-7 in the same model nematode species. Also, a class of short (small) interfering RNA (siRNA) involved in the process of RNA interference was discovered. Following these findings, the various number of miRNAs have been discovered and reported in mammals, and more than 700 miRNAs, which were identified in humans, have been fully sequenced (16).
MicroRNA and cancer

Proliferation, Differentiation, development, and metabolism are examples of multiple biological functions of this class RNAs. In addition, miRNAs are playing an important role in cancer, diabetes, autism, fragile X syndrome, Alzheimer’s, and heart diseases (17-20). Cancer has been known as a common complex disease worldwide. Series of genetic and epigenetic factors alter certain balances, which cause uncontrolled cellular proliferation. Due to the complexity of cancer, a single therapeutic strategy will not be able to produce a lasting cure. MiRNAs, however, got the capacity to target several protein-coding genes at the same time. As a result, a small change in miRNA expression can lead to meaningful alterations in the expression profile of several protein-coding genes and, therefore, cause changes in cellular phenotype (21-23). MiRNAs can be classified as oncomiR and tumor suppressor miRNAs from which a large number of can be used as diagnostic and prognostic biomarkers of the cancers (24,25).

Tumor formation is the result of alterations in miRNA expression by decreasing the expression of necessary genes that are needed in the proliferation or survival of the cells. However, in another study, it has been indicated that cancer progression or tumorigenesis does not contribute directly to miRNA (26). It is not completely found out that the changes in miRNA expression are either because of the pathological state of cancer or the cancer is the direct reason for it. Nevertheless, miRNA expression is affected directly or indirectly by several alterations that happen in cancer cells. Some changes such as gene mutations, changes in epigenetic regulation of miRNA, abnormalities in miRNA genes, or proteins that are involved in their construction and genomic rearrangements are some of the examples of alterations that might affect miRNA expression.

One of the main factors of changing miRNA expression in tumor cells in the presence of miRNAs in tumor-related genomic regions or fragile genomic areas. This specifically causes influences miRNA and mRNA connectivity features, which can be named the direct effect of the mutations. Incomplete translational processes are the result of altered miRNA interactions (27). MiRNAs are capable of regulating a broad set of genes efficiently and silence target genes simultaneously. Since cancer is a heterogenic disease, miRNA’s characteristic features are beneficial for treatment. MiRNAs target cancer cells in spite of targeting endothelial cells and fibroblasts. This helps the inhibiting of angiogenesis and tumor fibrosis. Therefore, the required process during metastasis and tumor formation is blocked (28). Moreover, disregulated miRNAs are implicated in the pathogenesis of cancer due to having an effect on oncogenes and/or tumor suppressor genes (29,30).

MicroRNAs function

The role of miRNA in cancer has already been intensively evaluated, and either clinical studies or in vitro and in vivo experiments demonstrated their importance on this occasion (23). MiRNA’s role was first studied in association with chronic lymphocytic leukemia (CLL) (31). Later multiple miRNAs were reported in accordance with plenty of other cancers (32-40). The dysregulation of miRNAs is also linked to cancer in various studies (41-44). It has been proved that they play important roles in metastasis, initiation, and progression, as well as therapeutic resistance (44). There also exists researches describing miRNAs playing two separate acts in carcinogenesis (to be both as “oncomirs” and as “tumor suppressors”) (45-48). In support of this thought, scientists demonstrated the fact that miRNA expression can be up- or down-regulated in cancer cells in comparison with normal cells. They also seem to be deregulated in hematological malignancies, as well as many solid tumors (42,49,50). When it comes to location, however, about 50% of miRNA genes are embedded in genomic instability regions (51). This strengthens the evidence of cancer being related to miRNAs. Besides, miRNAs regulate 20-30% of all protein-coding genes (52,53), which supports the probability of miRNA’s signature, providing efficient information about tumors (49).

Notably, expression patterns of miRNAs are tumor- and tissue-specific (32,54,55). For example, miR-155 is a multifunctional miRNA and is involved in inflammation, immune response, and cancer development (56), over-expressed in leukemia and lymphoma (57-60), and down-regulated in melanoma, gastric cancer, ovarian cancer, and endocrine tumors (61-65). These capabilities make miRNAs valuable agents for diagnosis and therapy of certain kinds of cancer. Another example of cancer-specific miRNAs is miR-21, which has been investigated by several groups. Subsequently, scientists found out that miR-21 is over-expressed in malignancies like a breast (50), colon (66), lung (32), liver (67), thyroid (68), and leukemia (32). These findings suggested that this oncomir is a good example of a cancer-specific miRNA (69).

Dysfunction or misexpression of miRNA can affect a broad range of processes involved in tumor progresses.
such as metastasis, apoptosis, angiogenesis, and cell cycle regulation (70-75). There are reports of five families of miRNA who target cell cycle regulators. These miRNAs are the let-7, the miR-15a/16 cluster, miR-34 families, the miR-17/20 cluster, and the miR-221/222 cluster. The entitled miRNAs are capable of controlling cell cycle checkpoints. Malfunction of these miRNAs may cause a rise in cell proliferation, which is necessary for tumor growth (76). However, some studies demonstrated miRNAs as anti-apoptotic regulators of key pathways in cancer. These miRNAs are highlighted to maintain cancer cell survival and drug resistance contribution (77). Besides, pro-apoptotic miRNAs serving as anti-cancer agents (78). The miRNAs also play a key role in the metabolism of cancer cells (79). They regulate nutrient uptake, targeting transporters, and metabolic enzymes and modulating cancer cell metabolism. They increase the accumulation of materials to control metabolic flux and support proliferation (80,81). We summarized some important onco-miRNAs and their functions in Table 1.

Table 1. Some important onco-miRNA and their function

| MicroRNAs     | Target gene(S) or Protein          | Function                                               |
|---------------|-----------------------------------|--------------------------------------------------------|
| miR 15 and miR 16 | NA                               | B-cell lymphocytic, chronic Leukemia                   |
| miR-17 ~ 92 cluster | NA                               | Lung and other malignancies                            |
| miR-21         | Pdc4, BMPRII & LRRFIP1            | Tumorigenesis and angiogenesis                         |
| miR-155        | TP53INP1                          | Promote apoptosis through activation of caspases       |
| miR-371 ~ 3    | LATS2                             | Overexpression in pancreatic cancer and breast cancer progression |

Metastasis-mediating miRNAs have also been discovered. They regulate distinct steps of the metastasis, affecting both signaling pathways in the cancer cell and interactions of cells with one another and with tumor stroma. According to studies, they can activate or suppress metastasis (82,83). Some miRNAs are implicated in suppressing apoptosis and stimulating tumorigenesis (84). Other miRNA families contribute to both tumor growth and metastasis (38). They are able to silence multiple oncogenes and are down-regulated in several tumors (85,86). Pro-metastatic miRNAs, however, are another example of metastasis-promoting miRNAs (87,88). Subsequently, due to the important role of miRNAs in cancer, there exists a wide range of strategies based on miRNA in oncology. They can be used for cancer classification (49,89) or tissue origin identification of cancers with the unknown primary origin (90,91). Their expression can serve as a useful prognostic or diagnostic marker (92-95). Interestingly, miRNA signatures have been established as predictive factors of response to therapy (96-100) and drugs (101,102).

MicroRNA in cancer therapy

Since miRNAs discovery, a debate has risen that miRNAs could be regarded as a promising biomarker to...
improve response to cancer treatment (26). The advent of miRNA-based therapy, however, has opened new avenues to use targeted therapy for clinical applications, since there are some limitations for current cancer therapies (103). All of the applications in the previous section are possible when dealing with primary tumors. The fact that miRNAs are more stable than mRNAs is the key point since this stability enables them to be detected in the circulation and serve as biomarkers. Circulating miRNAs can be measured with regard to a wide variety of cancers (104). Therefore, studies are currently highlighting their employment in cancer therapeutics (105). Based on several studies in recent years, miRNAs can be used as highly potential molecules in CRC therapy (30). Several therapeutic strategies associated with miRNAs can prevent cancer progression (Figure 2).

Figure 2. Different miRNA-based therapeutic strategies against cancer progression, metastasis, and resistance to therapy

Some examples include cutting oncogenic miRNAs by artificial miRNAs, which are capable of pairing with mRNAs, inhibition of the entitled oncogenic miRNAs, inducing the tumor suppressor miRNAs, or decreasing miRNA expression using various epigenetic factors like promoter methylation. To reduce the miRNA expression, antisense oligonucleotides can also be used. They are particularly paired with miRNA (26). One type that is artificially made is Antagomir (106). In comparison with other cancer treatment methods, these molecules are less toxic and create stable inhibition (27).

MiRNAs can also be agents or targets of cancer therapy according to their function, stage of cancer, and type of cancer (107). In order to use combined therapies targeting multiple miRNAs, tumor-secreted miRNA, who are messengers and/or effectors, must be characterized as the first step. Due to the correlation between their levels and metastasis, circulating or exosomal miRNAs can be quantified to select patients with high risks of metastasis in a certain type of cancer. As a result, these patients will benefit from a preventive strategy that targets the miRNA effectors (108). There also have been studies indicating that treatment interventions such as inhibition of oncomiRs and restoration of tumor suppressor miRNAs might be beneficial for certain types of cancers (25).

In addition to the fact that cell-free miRNAs are functionally effective in metastatic progression, they are also nominated for potential novel therapeutic targets (108,109). An interesting advantage of cell-free miRNAs is that their expression levels can be monitored when treatment is started (110). In this regard circulating miRNAs are discovered to be potential diagnostic and therapeutic agents in association with cancers (111). Another aspect of targeting miRNAs is that they are observed to be beneficial for improved response to drugs. Hence, circulating miRNA’s expression level in blood is useful for prognosis determination (102,112). Moreover, compared to other gene-therapy methods and drug molecules, miRNA showed low toxicity (101). Accordingly, in case of safe delivery to cancer cells, miRNA-based therapeutics seems to be promising anti-cancer guardians.

Once miRNAs discovered, significant progress in the identification of these novel family has confirmed that these small and non-coding RNAs are a numerous class of regulatory RNAs. Also, the skeleton of a biochemical mechanism for their functions in gene regulation has specified. The most attractive part of miRNA therapeutics is their capability to target any genes, which is not possible or difficult by protein-based drugs or small molecules. Nowadays, cancer is the most important target of miRNA therapeutics among the numerous diseases being studied. We briefly clarified the particular roles and the importance of miRNAs in the regulation of gene expression. Additionally, the specific mechanisms by which miRNA mediated repression needs more research and study.
MicroRNA and cancer

Acknowledgments

The authors would like to thank the Immunology Research Center, Tabriz University of Medical Sciences, for their support.

References

1. Ling H, Zhang W, Calin GA. Principles of microRNA involvement in human cancers. Chin J Cancer 2011;30:739-48.
2. Mattick JS, Makunin I V. Non-coding RNA. Hum Mol Genet 2006;15:17-29.
3. Mirakholi M, Mahmoudi T, Heidari M. MicroRNAs Horizon in Retinoblastoma. Acta Med Iran. 51(12):823-829.
4. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
5. Lee Y, Jeon K, Lee JT, Kim S, Kim VN. MicroRNA maturation: Stepwise processing and subcellular localization. EMBO J 2002;21:4663-70.
6. Han J, Lee Y, Yeom K-H, Kim Y-K, Jin H, Kim VN. The Drosophila Dicer-2 complex in primary microRNA processing. Genes Dev 2004;18:3016-27.
7. Yi R, Qin Y, Macara IG, Cullen BR. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 2003;17:3011-6.
8. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005;120:15-20.
9. Denli AM, Tops BBJ, Plasterk RHA, Ketting RF, Hannon GJ. Processing of primary microRNAs by the Microprocessor complex. Nature 2004;432:231-5.
10. Bartel DP. MicroRNAs: Target Recognition and Regulatory Functions. Cell 2009;136:215-33.
11. Siomi H, Siomi MC. Posttranscriptional Regulation of MicroRNA Biogenesis in Animals. Mol Cell 2010;38:323-32.
12. Bhayani MK, Calin GA, Lai SY. Functional relevance of miRNA* sequences in human disease. Mutat Res 2012;731:14-9.
13. Wiemer EAC. The role of microRNAs in cancer: No small matter. Eur J Cancer 2007;43:1529-44.
14. Janssens MD, Lund AH. MicroRNA and cancer. Mol Oncol 2012;6:590-610.
15. Ambros V. The functions of animal microRNAs. Nature 2004;431:350-5.
16. Mohammadi A, Mansoori B, Baradaran R. Regulation of microRNAs by herbal medicine: An emerging field in cancer therapies. Biomed Pharmacother 2017;86:262-70.
17. Le Quesne J, Caldas C. Micro-RNAs and breast cancer. Mol Oncol 2010;4:230-41.
18. Almeida MI, Reis RM, Calin GA. MicroRNA history: Discovery, recent applications, and next frontiers. Mutat Res 2011;717:1-8.
19. Shenouda SK, Alahari SK. MicroRNA function in cancer: Oncogene or a tumor suppressor? Cancer Metastasis Rev 2009;28:369-78.
20. Huang Y, Shen XJ, Zou Q, Wang SP, Tang SM, Zhang GZ. Biological functions of microRNAs: A review. J Physiol Biochem 2011;67:129-39.
21. Mohammadzadeh R, Baradaran B, Valizadeh H, Yousefi B, Zakeri-Milani P. Reduced ABCB1 expression and activity in the presence of acrylic copolymers. Adv Pharm Bull 2014;4:219-24.
22. Sárez Y, Sessa WC. MicroRNAs as Novel Regulators of Angiogenesis. Circ Res 2009;104:442-54.
23. Spizzo R, Nicoloso MS, Croce CM, Calin GA. SnapShot: MicroRNAs in Cancer. Cell 2009;137:586.e1.
24. Wang JY, Huang JC, Chen G, Wei DM. Expression level and potential target pathways of miR-1-3p in colorectal carcinoma based on 645 cases from 9 microarray datasets. Mol Med Rep 2018;17:5013-20.
25. Karimi-Dermani F, Azizi Jalilian F, Hossienkhani H, Ezati R, Amini R. siRNA Delivery Technology for Cancer Therapy: Promise and Challenges. Acta Med Iran. 57(2):83-93.
26. Shirjarg S, Mansoori B, Asghari S, Duijf PHG, Mohammad M, Gjerstorff M, et al. MicroRNAs in cancer cell death pathways: Apoptosis and necroptosis. Free Radic Biol Med. 2019;139:1-15.
27. Schaefer A, Jung M, Kristiansen G, Lein M, Schrader M, Miller K, et al. MicroRNAs and cancer: Current state and future perspectives in urologic oncology. Urol Oncol 2010;28:4-13.
28. Plummer PN, Freeman R, Taft RJ, Vider J, Sax M, Umer BA, et al. MicroRNAs regulate tumor angiogenesis modulated by endothelial progenitor cells. Cancer Res 2013;73:341-52.
29. Mansoori B, Mohammad A, Ghasabi M, Shirjarg S, Dehghan R, Montazeri V, et al. miR-142-3p as tumor suppressor miRNA in the regulation of tumorigenicity, invasion and migration of human breast cancer by targeting Bach-1 expression. J Cell Physiol. 2019;234:9816–25.
30. Slaby O, Svoboda M, Michalek J, Vyzula R. MicroRNAs in colorectal cancer: Translation of molecular biology into clinical application. Mol Cancer 2009;8:102.
31. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Nonlinear partial differential equations and applications: Frequent deletions and down-regulation of
micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99:15524-9.

32. Moazeni M, Khoramizadeh MR, Teimoori-Toolabi L, Noorbakhsh F, Rezaie S. The Effect of EFG1 Gene Silencing on Down-Regulation of SAP5 Gene, by Use of RNAi Technology. Acta Med Iran. 52:9-14.

33. Calin GA, Cimmino A, Fabbri M, Ferracin M, Wojcik SE, Shimizu M, et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A. 2008;105:5166-71.

34. Deng M, Tang H, Zhou Y, Zhou M, Xiong W, Zheng Y, et al. Mir-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma. J Cell Sci 2011;124:2997-3005.

35. Díaz R, Silva J, García JM, Lorenzo Y, García V, Peña C, et al. Deregulated expression of miR-106a predicts survival in human colon cancer patients. Genes Chromosomes Cancer 2008;47:794-802.

36. Drakaki A, Iliopoulos D. MicroRNA-gene signaling pathways in pancreatic cancer. Biomed J 2013;3:200-8.

37. Hirata H, Ueno K, Shahryari V, Tanaka Y, Tabatabai ZL, Hinoda Y, et al. Oncogenic microRNA-182-5p Targets Smad4 and RECK in Human Bladder Cancer. PLoS One 2012;7:1-8.

38. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. Reduced expression of the let-7 microRNAs in human lung cancers with shortened postoperative survival. Cancer Res 2004;64:3753-6.

39. Macha M, Seshacharyulu P, Krishn S, Pai P, Rachagani S, Jain M, et al. MicroRNAs (miRNAs) as Biomarker(s) for Prognosis and Diagnosis of Gastrointestinal (GI) Cancers. Curr Pharm Des 2014;20:5287-97.

40. Radhakrishnan P, Mohr AM, Grandgenett PM, Steele MM, Batra SK, Hollingsworth MA. MicroRNA-200c Modulates the Expression of MUC4 and MUC16 by Directly Targeting Their Coding Sequences in Human Pancreatic Cancer. PLoS One 2013;8:e73356.

41. Lee YS, Dutta A. MicroRNAs in Cancer. Annu Rev Pathol 2009;4:199-227.

42. Garzon R, Calin GA, Croce CM. MicroRNAs in Cancer. Annu Rev Med 2009;60:167-79.

43. Meltzer PS. Small RNAs with big impacts. Nature 2005;435:745-6.

44. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66.

45. Welch C, Chen Y, Stallings RL. MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 2007;26:5017-22.

46. He L, Thomson JM, Hemann MT, Hernandez-Monge E, Mu D, Goodson S, et al. A microRNA polyclastron as a potential human oncogene. Nature. 2005;435:828-33.

47. Yu S, Lu Z, Liu C, Meng Y, Ma Y, Zhao W, et al. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer. Cancer Res 2010;70:6015-25.

48. Esquela-Kerscher A, Slack FJ. Oncomirs - MicroRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-69.

49. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8.

50. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65:7065-70.

51. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A 2004;101:2999-3004.

52. Bentwich I, Avniel A, Karov Y, Aharonov R, Gilad S, Barad O, et al. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 2005;37:766-70.

53. Carthew RW. Gene regulation by microRNAs. Curr Opin Genet Dev 2006;16:2038.

54. Sood P, Krek A, Zavolan M, Macino G, Rajewsky N. Cell-type-specific signatures of microRNAs on target mRNA expression. Proc Natl Acad Sci U S A 2006;103:2746-51.

55. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-98.

56. Faraoni I, Antonetti FR, Cardone J, Bonmassar E. miR-155 gene: A typical multifunctional microRNA. Biochim Biophys Acta - Mol Basis Dis 2009;1792:497-505.

57. Grether T, Grochola LF, Udelnow A, Lautenschläger C, Würl P, Taubert H. Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer 2010;126:73-80.

58. Jiang S, Zhang HW, Lu MH, He XH, Li Y, Gu H, et al. MicroRNA-155 functions as an oncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 2010;70:3119-27.

59. Pedersen IM, Otero D, Kao E, Miletic AV, Hother C, Ralfkiaer E, et al. Onco-miR-155 targets SHIP1 to promote TNFα-dependent growth of B cell lymphomas. EMBO Mol Med 2009;1:288-95.

60. Ryu JK, Hong SM, Karikari CA, Hruban RH, Goggins

M. Maralani, et al.
MicroRNA and cancer

MG, Maitra A. Aberrant microRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology 2010;10:66-73.

61. Roldo C, Missaglia E, Hagan JP, Falconi M, Capelli P, Bersani S, et al. MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 2006;24:4677-84.

62. Li CL, Nie H, Wang M, Su LP, Li JF, Yu YY, et al. microRNA-155 is downregulated in gastric cancer cells and involved in cell metastasis. Oncol Rep 2012;27:1960-6.

63. Rokah OH, Granot G, Ovcharenko A, Modai S, Pasmanik-Chor M, Toren A, et al. Downregulation of miR-31, miR-155, and miR-564 in chronic myeloid leukemia cells. PLoS One 2012;7:e35501.

64. Dahia N, Sherman-Baust CA, Wang TL, Davidson B, Shih LM, Zhang Y, et al. MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One 2008;3:e2436.

65. Levati L, Pagani E, Romani S, Castiglia D, Piccinni E, Covaci C, et al. MicroRNA-155 targets the SKI gene in human melanoma cell lines. Pigment Cell Melanoma Res 2011;24:538-50.

66. Asangani IA, Rasheed SA, Nikolaova DA, Leopuld JH, Collburn NH, Post S, et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008;27:2128-36.

67. Badalá F, Nouri-mahdavi K, Raooof DA, Meng, Fanyin, Henson, et al. MicroRNA-21 Regulates Expression of the PTEN Tumor Suppressor Gene in Human Hepatocellular Cancer. Gastroenterology 2007;133:647-58.

68. Tetzlaff MT, Liu A, Xu X, Master SR, Baldwin DA, Tobias JW, et al. Differential expression of miRNAs in papillary thyroid carcinoma compared to multinodular goiter using formalin fixed paraffin embedded tissues. Endocr Pathol 2007;18:163-73.

69. Tran N, McLean T, Zhang X, Zhao CJ, Thomson JM, O’Brien C, et al. MicroRNA expression profiles in head and neck cancer cell lines. Biochem Biophys Res Commun 2007;358:12-7.

70. Ell B, Mercatali L, Ibrahim T, Campbell N, Schwarzenbach H, Pantel K, et al. Tumor-Induced Osteoclast miRNA Changes as Regulators and Biomarkers of Osteolytic Bone Metastasis. Cancer Cell 2013;24:542-56.

71. Korpal M, Lee ES, Hu G, Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J Biol Chem 2008;283:14910-4.

72. Erson AE, Petty EM. MicroRNAs in development and disease. Clin Genet 2008;74:296-306.

73. Ceppi P, Muddulutur G, Kumarswamy R, Rapa I, Scaglioni G V., Papotti M, et al. Loss of miR-200c expression induces an aggressive, invasive, and chemo-resistant phenotype in non-small cell lung cancer. Mol Cancer Res 2010;8:1207–16.

74. Eulalio A, Huntzinger E, Nishihara T, Reh winkel J, Fauser M, Izaurralde E. Deadenylation is a widespread effect of miRNA regulation. Rna 2009;15:21-32.

75. Lundstrom K. Micro-RNA in Disease and Gene Therapy. Curr Drug Discov Technol 2011;8:76-86.

76. Yu Z, Baserga R, Chen L, Wang C, Lisanti MP, Pestell RG. MicroRNA, cell cycle, and human breast cancer. Am J Pathol 2010;176:1058-64.

77. Lina RT, Busacca S, Almeida GM, Gaudino G, Fen nell DA, Vasconcelos MH. MicroRNA regulation of core apoptosis pathways in cancer. Eur J Cancer 2011;47:163-74.

78. Cimmino A, Calin GA, Fabbri M, Iorio M V., Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005;102:13944-9.

79. Chen B, Li H, Zeng X, Yang P, Liu X, Zhao X, et al. Roles of microRNA on cancer cell metabolism. J Transl Med 2012;10:1.

80. Koh HJ, Toyoda T, Fujii N, Jung MM, Rathod A, Middelbeek RJW, et al. Sucrose nonfermenting AMPK-related kinase (SNARK) mediates contraction-stimulated glucose transport in mouse skeletal muscle. Proc Natl Acad Sci U S A 2010;107:15541-6.

81. Dávalos A, Goedeke L, Smibert P, Ramírez CM, Warrier NP, Andreu U, et al. miR-33a/b contribute to the regulation of fatty acid metabolism and insulin signaling. Proc Natl Acad Sci U S A 2011;108:9232-7.

82. Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA. MicroRNAs-The micro steering wheel of tumour metastases. Nat Rev Cancer 2009;9:293-302.

83. Ma L, Weinberg RA. Micromanagers of malignancy: role of microRNAs in regulating metastasis. Trends Genet 2008;24:448-56.

84. Li J, Huang H, Sun L, Yang M, Pan C, Chen W, et al. MiR-21 indicates poor prognosis in tongue squamous cell carcinomas as an apoptosis inhibitor. Clin Cancer Res 2009;15:3998-4008.

85. Mayr C, Hemann MT, Bartel DP. Disrupting the Pairing Between let-7 and Hmg2 Enhances Oncogenic Transformation. Science 2007;315:1576-9.

86. Koscianska E, Baev V, Skreka K, Oikonomaki K, Rusinov V, Kalantidis K. Prediction and preliminary
validation of oncogene regulation by miRNAs. BMC Mol Biol 2007;8:1-14.
87. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007;449:682-8.
88. Huang Q, Gumireddy K, Schrier M, le Sage C, Nagel R, Nair S, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 2008;10:202-10.
89. Sempere LF, Christensen M, Silahtaroglu A, Bak M, Heath C V., Schwartz G, et al. Altered microRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res 2007;67:11612-20.
90. Rosenwald S, Gilad S, Benjamin S, Lebanony D, Dromi N, Faerman A, et al. Validation of a microRNA-based qRT-PCR test for accurate identification of tumor tissue origin. Mod Pathol 2010;23:814-23.
91. Rosenfeld N, Aharonov R, Meiri E, Rosenwald S, Spector Y, Zepeniuk M, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 2008;26:462-9.
92. Ferracin M, Veronese A, Negrini M. Micromarkers: miRNAs in cancer diagnosis and prognosis. Expert Rev Mol Diagn 2010;10:297-308.
93. Gallardo E, Navarro A, Viñolas N, Marrades RM, Díaz T, Gel B, et al. miR-34a as a prognostic marker of relapse in surgically resected non-small-cell lung cancer. Carcinogenesis 2009;30:1903-9.
94. Okamoto T, Miyazaki Y, Inase N. Genetic background of hypersensitivity pneumonitis. Japanese J Chest Dis 2010;69:701-8.
95. Ota D, Mimori K, Yokobori T, Iwatsuki M, Kataoka A, Masuda N, et al. Identification of recurrence-related microRNAs in the bone marrow of breast cancer patients. Int J Oncol 2011;38:955-62.
96. Yang H, Kong W, He L, Zhao JJ, O’Donnell JD, Wang J, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res 2008;68:425-33.
97. Weiss GJ, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA, et al. EGFR regulation by microRNA in lung cancer: Correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. Ann Oncol 2008;19:1053-9.
98. Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology 2008;47:897-907.
99. Giovannetti E, Funel N, Peters GJ, Del Chiario M, Erozenci LA, Vasile E, et al. MicroRNA-21 in pancreatic cancer: Correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 2010;70:4528-38.
100. Rodriguez-González FG, Sieuwerts AM, Smit M, Look MP, Meijer-Van Gelder ME, De Weerd V, et al. MicroRNA-30c expression level is an independent predictor of clinical benefit of endocrine therapy in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat 2011;127:43-51.
101. Kota J, Chivukula RR, O’Donnell KA, Wentzel EA, Montgomery CL, Hwang H, et al. Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model. Cell 2009;137:1005-17.
102. Iorio MV, Casalini P, Piovan C, Leva G Di, Merlo A, Triulzi T, et al. MicroRNA-205 regulates HER3 in human breast cancer. Cancer Res 2009;69:2195-200.
103. Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, et al. Efficacy of Gefitinib, a Tyrosine Kinase Inhibitor of EGFR, in Non-Small-Cell Lung Cancer: A Randomized Trial. JAMA 2009;301:2149-58.
104. Iorio MV, Croce CM. MicroRNA dysregulation in cancer: Diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med 2012;4:143-59.
105. Zhang Y, Wang Z, Gemeinhart RA. Progress in microRNA delivery. J Control Release 2013;172:962-74.
106. Cho WCS. MicroRNAs: Potential biomarkers for cancer diagnosis, prognosis and targets for therapy. Int J Biochem Cell Biol 2010;42:1273-81.
107. Bader AG, Brown D, Stoudemire J, Lammers P. Developing therapeutic microRNAs for cancer. Gene Ther 2011;18:1121-6.
108. Si ML, Zhu S, Wu H, Lu Z, Wu F, Mo YY. miR-21-mediated tumor growth. Oncogene 2007;26:2799-803.
109. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010;12:247-56.
110. Krüttfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, et al. Silencing of microRNAs in vivo with “antagomirs.” Nature 2005;438:685-9.
111. Chen X, Liang H, Zhang J, Zen K, Zhang CY. Secreted microRNAs: A new form of intercellular communication. Trends Cell Biol 2012;22:125-32.
112. Mostert B, Sieuwerts AM, Martens JW, Sleijfer S. Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients. Expert Rev Mol Diagn 2011;11:259-75.